UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 844

Sortiert nach

FDA Approval: Blinatumomab

Clinical cancer research, 2015-09, Vol.21 (18), p.4035-4039

2015

Volltextzugriff (PDF)

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio

JAMA oncology, 2017-12, Vol.3 (12), p.1692

2017

Volltextzugriff (PDF)

Bortezomib for the Treatment of Mantle Cell Lymphoma

Clinical cancer research, 2007-09, Vol.13 (18), p.5291-5294

2007

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

Clinical cancer research, 2013-09, Vol.19 (17), p.4559-4563

2013

Volltextzugriff (PDF)

United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy

Clinical cancer research, 2006-05, Vol.12 (10), p.2955-2960

2006

Volltextzugriff (PDF)

Sorafenib for the Treatment of Advanced Renal Cell Carcinoma

Clinical cancer research, 2006-12, Vol.12 (24), p.7271-7278

2006

Volltextzugriff (PDF)

Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy

The oncologist (Dayton, Ohio), 2003-12, Vol.8 (6), p.508-513

2003

Volltextzugriff (PDF)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

The oncologist (Dayton, Ohio), 2009-01, Vol.14 (1), p.95-100

2009

Volltextzugriff (PDF)

Generic oncology drugs: are they all safe?

The lancet oncology, 2016-11, Vol.17 (11), p.e493-e501

2016

Volltextzugriff (PDF)

Pain palliation measurement in cancer clinical trials: The US Food and Drug Administration perspective

Cancer, 2014-03, Vol.120 (5), p.761-767

2014

Volltextzugriff (PDF)

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Clinical cancer research, 2015-06, Vol.21 (12), p.2666-2670

2015

Volltextzugriff (PDF)

Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products

JAMA : the journal of the American Medical Association, 2015-11, Vol.314 (19), p.2062

2015

Volltextzugriff (PDF)

Dexrazoxane (Totect™): FDA Review and Approval for the Treatment of Accidental Extravasation Following Intravenous Anthracycline Chemotherapy

The oncologist (Dayton, Ohio), 2008-04, Vol.13 (4), p.445-450

2008

Volltextzugriff (PDF)

FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma

Clinical cancer research, 2015-04, Vol.21 (7), p.1525-1529

2015

Volltextzugriff (PDF)

Routine Iron Supplementation and Screening for Iron Deficiency Anemia in Pregnancy

Annals of internal medicine, 2015-09, Vol.163 (5), p.399

Kane, Robert C

2015

Volltextzugriff (PDF)

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

Clinical cancer research, 2015-08, Vol.21 (16), p.3586-3590

2015

Volltextzugriff (PDF)

Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada

The oncologist (Dayton, Ohio), 2019-04, Vol.24 (4), p.537-548

2019

Volltextzugriff (PDF)

Caution in making inferences from FDA's Adverse Event Reporting System

American journal of health-system pharmacy, 2012-06, Vol.69 (11), p.922-923

2012

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Clinical cancer research, 2014-08, Vol.20 (15), p.3902-3907

2014

Volltextzugriff (PDF)

Re: potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer

JNCI : Journal of the National Cancer Institute, 2012-05, Vol.104 (9), p.717-718

Kane, Robert C

2012

Volltextzugriff (PDF)

The Clinical Significance of Statistical Significance

The oncologist (Dayton, Ohio), 2008-11, Vol.13 (11), p.1129-1133

Kane, Robert C.

2008

Volltextzugriff (PDF)

A possible association between fetal/neonatal exposure to radiofrequency electromagnetic radiation and the increased incidence of Autism Spectrum Disorders (ASD)

Medical hypotheses, 2004-01, Vol.62 (2), p.195-197

Kane, Robert C

2004

Volltextzugriff (PDF)

Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)

Cancer medicine (Malden, MA), 2017-07, Vol.6 (7), p.1541-1551

2017

Volltextzugriff (PDF)

Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction

The American heart journal, 2012-12, Vol.164 (6), p.846-855

2012

Volltextzugriff (PDF)

Accuracy of a single fecal occult blood test in screening for colorectal cancer

Annals of internal medicine, 2005-08, Vol.143 (3), p.235

Kane, Robert C

2005

Volltextzugriff (PDF)

1 – 25 von 844

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(745)
Mit Volltextzugriff
(703)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

FDA Approval: Blinatumomab

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio

Bortezomib for the Treatment of Mantle Cell Lymphoma

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy

Sorafenib for the Treatment of Advanced Renal Cell Carcinoma

Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

Generic oncology drugs: are they all safe?

Pain palliation measurement in cancer clinical trials: The US Food and Drug Administration perspective

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products

Dexrazoxane (Totect™): FDA Review and Approval for the Treatment of Accidental Extravasation Following Intravenous Anthracycline Chemotherapy

FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma

Routine Iron Supplementation and Screening for Iron Deficiency Anemia in Pregnancy

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada

Caution in making inferences from FDA's Adverse Event Reporting System

U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Re: potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer

The Clinical Significance of Statistical Significance

A possible association between fetal/neonatal exposure to radiofrequency electromagnetic radiation and the increased incidence of Autism Spectrum Disorders (ASD)

Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)

Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction

Accuracy of a single fecal occult blood test in screening for colorectal cancer

Suchergebnisse filtern